Diagnostic Utility of a Custom 34-Gene Anchored Multiplex PCR-Based Next-Generation Sequencing Fusion Panel for the Diagnosis of Bone and Soft Tissue Neoplasms With Identification of Novel USP6 Fusion Partners in Aneurysmal Bone Cysts
- PMID: 33147323
- DOI: 10.5858/arpa.2020-0336-OA
Diagnostic Utility of a Custom 34-Gene Anchored Multiplex PCR-Based Next-Generation Sequencing Fusion Panel for the Diagnosis of Bone and Soft Tissue Neoplasms With Identification of Novel USP6 Fusion Partners in Aneurysmal Bone Cysts
Abstract
Context.—: Bone and soft tissue tumors are heterogeneous, diagnostically challenging, and often defined by gene fusions.
Objective.—: To present our experience using a custom 34-gene targeted sequencing fusion panel.
Design.—: Total nucleic acid extracted from formalin-fixed, paraffin-embedded (FFPE) tumor specimens was subjected to open-ended, nested anchored multiplex polymerase chain reaction and enrichment of 34 gene targets, thus enabling detection of known and novel fusion partners.
Results.—: During a 12-month period, 147 patients were tested as part of routine clinical care. Tumor percentage ranged from 10% to 100% and turnaround time ranged from 3 to 15 (median, 7.9) days. The most common diagnostic groups were small round blue cell tumors, tumors of uncertain differentiation, fibroblastic/myofibroblastic tumors, and adipocytic tumors. In-frame fusion transcripts were identified in 64 of 142 cases sequenced (45%): in 62 cases, the detection of a disease-defining fusion confirmed the morphologic impression; in 2 cases, a germline TFG-GPR128 polymorphic fusion variant was detected. Several genes in the panel partnered with multiple fusion partners specific for different diagnoses, for example, EWSR1, NR4A3, FUS, NCOA2, and TFE3. Interesting examples are presented to highlight how fusion detection or lack thereof was instrumental in establishing accurate diagnoses. Novel fusion partners were detected for 2 cases of solid aneurysmal bone cysts (PTBP1-USP6, SLC38A2-USP6).
Conclusions.—: Multiplex detection of fusions in total nucleic acid purified from FFPE specimens facilitates diagnosis of bone and soft tissue tumors. This technology is particularly useful for morphologically challenging entities and in the absence of prior knowledge of fusion partners, and has the potential to discover novel fusion partners.
Similar articles
-
Histopathogenesis of bone- and soft-tissue tumor spectrum with USP6 gene rearrangement: multiple partners involved in the tissue repair process.Histol Histopathol. 2023 Mar;38(3):247-260. doi: 10.14670/HH-18-532. Epub 2022 Oct 7. Histol Histopathol. 2023. PMID: 36205240 Review.
-
Anchored multiplex PCR for targeted next-generation sequencing reveals recurrent and novel USP6 fusions and upregulation of USP6 expression in aneurysmal bone cyst.Genes Chromosomes Cancer. 2017 Apr;56(4):266-277. doi: 10.1002/gcc.22432. Epub 2016 Dec 2. Genes Chromosomes Cancer. 2017. PMID: 27910166
-
Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.Mod Pathol. 2019 May;32(5):609-620. doi: 10.1038/s41379-018-0175-7. Epub 2018 Nov 21. Mod Pathol. 2019. PMID: 30459475 Free PMC article.
-
Novel partners of USP6 gene in a spectrum of bone and soft tissue lesions.Virchows Arch. 2021 Jul;479(1):147-156. doi: 10.1007/s00428-021-03047-z. Epub 2021 Feb 9. Virchows Arch. 2021. PMID: 33558945
-
Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature.Skeletal Radiol. 2019 Jul;48(7):1059-1067. doi: 10.1007/s00256-018-3135-x. Epub 2019 Jan 2. Skeletal Radiol. 2019. PMID: 30603771 Review.
Cited by
-
USP6-associated soft tissue tumors with bone metaplasia: Clinicopathologic and genetic analysis and the identification of novel USP6 fusion partners.Front Oncol. 2023 Jan 16;12:1065071. doi: 10.3389/fonc.2022.1065071. eCollection 2022. Front Oncol. 2023. PMID: 36727055 Free PMC article.
-
Histopathogenesis of bone- and soft-tissue tumor spectrum with USP6 gene rearrangement: multiple partners involved in the tissue repair process.Histol Histopathol. 2023 Mar;38(3):247-260. doi: 10.14670/HH-18-532. Epub 2022 Oct 7. Histol Histopathol. 2023. PMID: 36205240 Review.
-
Ubiquitin-specific Peptidase 6 (USP6)-associated Fibroblastic/Myofibroblastic Tumors: Evolving Concepts.Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):93-101. doi: 10.21873/cgp.20244. Cancer Genomics Proteomics. 2021. PMID: 33608306 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical